Kristie L. Kahl

Articles

Olaparib Plus Neratinib Shows Early Potential in HER2+ Ovarian Cancer

March 19th 2019

Combination use of olaparib and neratinib may represent a novel therapeutic option for chemotherapy-resistant patients with HER2-positive, homologous recombination–proficient ovarian cancer tumors.

Neratinib Shows Promise in HER2-Mutant Cervical Cancer

March 19th 2019

Treatment with neratinib led to a clinical benefit rate of 54.5% in patients with HER2-mutant cervical cancer.

Pembrolizumab/Bevacizumab Regimen Induces Durable Responses in Ovarian Cancer

March 18th 2019

Combination therapy with pembrolizumab, bevacizumab, and metronomic cyclophosphamide induced a 95% disease control rate and 40% overall response rate among women with recurrent ovarian cancer.

Lenvatinib Combo Yields Favorable Responses in Ovarian, Endometrial Cancers

March 18th 2019

Lenvatinib in combination with weekly paclitaxel induced activity among those with recurrent endometrial and platinum-resistant epithelial ovarian cancer, resulting in a 65% overall response rate.

Individualized Dosing Reduces Niraparib-Related TEAEs in Ovarian Cancer Maintenance

March 17th 2019

Adverse events decreased among patients with high-risk ovarian cancer who received a 200- or 300-mg individualized starting dose of niraparib, based upon baseline bodyweight and platelet count, compared with a 300-mg fixed starting dose.

Repeat Use of PARP Inhibitors Could Be Effective Strategy in Ovarian Cancer

March 17th 2019

Prior exposure to PARP inhibitor treatment may not lead to resistance in future use with these agents in women with recurrent epithelial ovarian cancer, suggesting that repeat use could become more common.

Maintenance Niraparib Extends PFS Without Symptoms, Toxicities in Recurrent Ovarian Cancer

March 17th 2019

Patients with recurrent ovarian cancer who received niraparib maintenance therapy experienced more progression-free time without experiencing symptoms or toxicity compared with placebo; the benefit was 4-fold for those with germline (g) BRCA-mutated disease and 2-fold for non-gBRCA-mutated ovarian cancer.

Awareness Critical for Identifying irAEs Early in Breast Cancer

March 10th 2019

With tremendous advances and the accelerated approval of atezolizumab plus nab-paclitaxel for patients with unresectable locally advanced or metastatic PD-L1–positive triple-negative breast cancer, provider education in identifying associated toxicities from checkpoint inhibitor therapy is critical.

Addition of Alpelisib Prolongs PFS in PIK3CA-Mutant HR+, HER2- Advanced Breast Cancer Subgroups

March 9th 2019

The previously demonstrated progression-free survival benefit from the addition of alpelisib to fulvestrant appeared consistent among subgroups of patients with hormone receptor–positive/HER2-negative advanced breast cancer who have a PIK3CA mutation.

Study Validates Speed, Accuracy of Liquid Biopsies Identifying NSCLC Biomarkers

February 28th 2019

A liquid biopsy test detected all of the guideline-recommended biomarkers in newly diagnosed patients with metastatic non–small cell lung cancer at a similar rate but faster turnaround time to that of tissue genotyping.

Hormonal Agents Induce Improved OS in African Americans With Chemo-Naive mCRPC

February 12th 2019

African-American men with metastatic castration-resistant prostate cancer treated with novel hormonal therapies—namely abiraterone acetate or enzalutamide—lived 20% longer than their Caucasian counterparts.

FDA Delays Decision on Frontline Pembrolizumab sBLA in NSCLC

December 21st 2018

The FDA has extended the review period for a supplemental biologics license application for single-agent pembrolizumab for the frontline treatment of patients with locally advanced or metastatic nonsquamous or squamous non–small cell lung cancer with a PD-L1 expression level of ≥1% and no EGFR or ALK genomic tumor aberrations.

Oxybutynin Decreases Hot Flashes, Improves Quality of Life in Breast Cancer Survivors

December 7th 2018

Oxybutynin helped to reduce the frequency and intensity of hot flashes among women who could not take hormone replacement therapy in survivorship.

Association Between pCR and Neoadjuvant Chemo Shows Improved Breast Cancer Outcomes

December 6th 2018

Pathologic complete response following neoadjuvant chemotherapy appeared to be associated with improved survival outcomes among patients with breast cancer.

FDA Grants Atezolizumab Regimen Priority Review for Frontline SCLC

December 5th 2018

The FDA has granted a priority review designation to a supplemental biologics license application for atezolizumab for use in combination with carboplatin and etoposide for the frontline treatment of patients with extensive-stage small cell lung cancer.

Rivaroxaban May Reduce Blood Clot Risk During Active Systemic Cancer Therapy

December 4th 2018

Rivaroxaban may significantly reduce venous thromboembolism occurrence among patients actively being treated with systemic therapy, according to results from the phase IIIb CASSINI trial.

New Prediction Model Improves Personalized Insight Into MDS Survival

December 3rd 2018

An approach using machine learning to analyze genomic and clinical data from patients with myelodysplastic syndromes could replace the gold standard of predicting how long patients may live with the disease.

Beat AML Trial Proves Feasibility of Rapid Treatment Assignment Following Diagnosis

December 3rd 2018

Initial findings from the Beat AML study showed that rapid genetic testing in patients with AML was feasible and helpful, and that a precision medicine approach is possible for these patients, who must be treated urgently given the disease’s rapid progression.

First HCT Following CAR T-Cell Therapy Reduces Risk for ALL Relapse

December 2nd 2018

Receiving a stem cell transplant for the first time following CD19 CAR T-cell therapy induced a reduction in the risk for acute lymphoblastic leukemia (ALL) recurrence, according to a retrospective analysis of the phase I/II PLAT-02 study.

Luspatercept Reduces Blood Transfusion Dependence in Lower-Risk MDS Anemia

December 2nd 2018

Treatment with luspatercept significantly reduced the need for frequent red blood cell transfusions in nearly 53% of patients with anemia associated with low- to intermediate-risk myelodysplastic syndrome.